Buscar
🇪🇸
MEM
O
RY
.COM
4.37.48
Invitado
Iniciar sesión
Página de inicio
0
0
0
0
0
Crear curso
Cursos
Último juego
Panel
Notificaciones
Clases
Carpetas
Exámenes
Exámenes personalizados
Ayuda
Marcador
Tienda
Premios
Amigos
Asignaturas
Modo oscuro
Identificador de usuario: 999999
Versión: 4.37.48
www.memory.es
Estás en modo de exploración. debe iniciar sesión para usar
MEM
O
RY
Inicia sesión para empezar
Index
»
PHARMACOLOGY 2
»
Disorders of Blood
»
Level 2
level: Level 2
Questions and Answers List
Anticoagulants
level questions: Level 2
Question
Answer
Parenteral Anticoagulants
1 Heparin 2 Low-Molecular-Weight Heparins 3 Fondaparinux (Arixtra®) 4 Direct Thrombin Inhibitors
Oral Anticoagulants
1 WARFARIN 2 Dabigatran etexilate
are the two traditional anticoagulants used for acute coronary syndromes, deep-vein thrombosis (DVT), pulmonary embolism (PE), and heart surgery Also given to certain people at risk for forming blood clots, such as those with artificial heart valves or who have atrial fibrillation (AF)intravascular coagulation of the blood in any part of the circulatory system, as in the heart, arteries, veins, or capillaries
Heparin and warfarin
• Rapid-acting anticoagulant fast-acting, has a short half-life Uses: • Pulmonary embolism (PE), Stroke evolving, Massive deep venous thrombosis (DVT) Sources: ✓Lungs of cattle, Intestines of pigs Adverse effects • Hemorrhage, Thrombocytopenia, Hypersensitivity, Protamine Sulfate as antidote, Activated partial thromboplastin time IT NEEDS MONITORING w/ SPECIAL BLOOD TESTS
Heparin (unfractionated)
is produced by chemically splitting heparin into pieces of about one-third of its original size. fewer side effects, longer half-life, and a more predictable dose-dependent response, NO MONITORING req. INHIBITS FACTOR 10a Therapeutic use • Prevention of DVT following surgery • Treatment of established DVT • Prevention of ischemic complications Adverse effects and interactions • Bleeding • thrombocytopenia
Low-Molecular-Weight Heparins
• Synthetic anticoagulant, Selective inhibition longer half-life, less bleeding than LMW Heparins Therapeutic use • Prevention of DVT following surgery • Treatment of acute PE (in conjunction with warfarin) • Treatment of acute DVT (in conjunction with warfarin) Adverse effects • Bleeding • Patients weighing less than 50 kg • Thrombocytopenia • Spinal or epidural hematoma
Fondaparinux (Arixtra®)
Therapeutic use: Prevent clot formation (combined with aspirin) Mechanism of action • Facilitates the actions of antithrombin • Prevents the conversion of fibrinogen into fibrin • Prevents the activation of factor XIIIa Adverse effects • Back pain • Nausea • Headache
Direct Thrombin Inhibitors • Bivalirudin [Angiomax], Lepirudin, Argatroban, Desirudin
• Antagonist to vitamin K; Blocks the biosynthesis of factors VII, IX, X, and prothrombin It takes days to be effective Therapeutic uses - Long-term prophylaxis of thrombosis • Prevention of venous thrombosis and associated pulmonary embolism • Prevention of thromboembolism (in patients with prosthetic heart valves) • Prevention of thrombosis during atrial fibrillation Adverse effects • Hemorrhage (Fetal hemorrhage in pregnant) • Not to be Used during lactation Drug interactions • Drugs that increase anticoagulant effects • Drugs that promote bleeding
WARFARIN
• is a new oral direct thrombin inhibitor and the prodrug of dabigatran • is a small molecule that reversibly inhibits both free and clot-bound thrombin by binding to exosite 1 and/or the active site of thrombin
Dabigatran etexilate
Future of Anticoagulants 1 Molecular targets are __ 2 The two candidate compounds
. 1 factor IIa (thrombin) and factor Xa 2 direct thrombin inhibitor (dabigatran etexilate), direct factor Xa inhibitor (rivaroxaban)
an essential cofactor for the synthesis of many clotting factors.
Vitamin K
1 Heparin’s action can be reversed with __ 2 __ given orally or intravenously, can counteract warfarin.
1 protamine 2 Vitamin K
Specific antidotes for direct oral anticoagulants: 1 for Dabigatran 2 for Apixaban, Betrixaban, Edoxaban, Rivaroxaban
. 1 Idarucizumab (IV) 2 Andexanet alfa (IV volus then slow IV infusion)